AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18698222
Drug: Valsartan/Lisinopril 320/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Lisinopril 320/20 mg
Trial: 14743888
Drug: Oxaliplatin in
RxNorm normalized name: oxaliplatin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin in combination with 5-fluoro-uracil (5-FU) and leucovorin
Trial: 14743888
Drug: Oral prodrugs
RxNorm normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prodrugs of 5-FU (capecitabine and uracil)
Trial: 14743888
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies and small molecules targeting EGFR and VEGF
Trial: 10899744
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 300 mg extractum Valerianae radix siccum dragées LI 156
Trial: 10899744
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 5 mg oxazepam dragées
Trial: 8970248
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% solution
Trial: 8970248
Drug: Betaxolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.25% suspension
Trial: 6344893
Drug: Indoprofen 400
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 400 mg (i.v. bolus + 2-h infusion)
Trial: 6344893
Drug: Indoprofen 400
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 400 mg (i.v. bolus alone)
Trial: 26420269
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (dorsolateral prefrontal cortex group)
Trial: 26420269
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (cingulo-opercular network group)
Trial: 26420269
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (motor primary cortex group)
Trial: 24144788
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice daily with concomitant aspirin
Trial: 24144788
Drug: Warfarin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin with concomitant aspirin
Trial: 24144788
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice daily without concomitant aspirin
Trial: 24144788
Drug: Warfarin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin without concomitant aspirin
Trial: 17466461
Drug: Routine burn
RxNorm normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine burn rehabilitation treatment
Trial: 9711448
Drug: Orlistat 360
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 360 mg/day for 12 weeks
Trial: 2677374
Drug: H142 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H142 at 1.0 mg/kg/h
Trial: 2677374
Drug: H142 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H142 at 5.0 mg/kg/h
Trial: 2677374
Drug: H142 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H142 (all doses)
Trial: 356925
Drug: multivitamin‐electrolyte‐preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multivitamin‐electrolyte‐preparation
Trial: 30076614
Drug: Terlipressin (2-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2-12 mg/day)
Trial: 31007053
Drug: Group-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based occupational therapy (Group BOT, n=43)
Trial: 28027937
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (GTN)
Trial: 25998582
Drug: Tamsulosin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 400 μg
Trial: 21712498
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg/day)
Trial: 15618271
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor antagonist (540 mg oral fexofenadine hydrochloride; Allegra)
Trial: 15618271
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no H1 receptor antagonist)
Trial: 12518534
Drug: Eradication of
RxNorm normalized name: Combinations for eradication of Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication of Helicobacter pylori infection using triple therapy (pantoprazole + amoxicillin + clarithromycin)
Trial: 9578506
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (18 units/m2 per week divided into daily s.c. doses) for 1 year
Trial: 9578506
Drug: IGF‐I generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I generation test after GH injection
Trial: 7645033
Drug: MMF 2
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2 g treatment group (1.0 g b.i.d.)
Trial: 7645033
Drug: MMF 3
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3 g treatment group (1.5 g b.i.d.)
Trial: 7645033
Drug: Azathioprine group
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine group (1-2 mg/kg/day)
Trial: 7645033
Drug: MMF 2
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2 g treatment group
Trial: 7645033
Drug: MMF 3
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3 g treatment group
Trial: 2694923
Drug: 4 capsules
RxNorm normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules (1.26 g omega-3 fatty acids)
Trial: 2694923
Drug: 8 capsules
RxNorm normalized name: INGREZZA 40 MG / 80 MG Starter Pack, 28 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 capsules (2.52 g omega-3 fatty acids)
Trial: 2694923
Drug: Low-dose fish
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fish oil (4 capsules)
Trial: 582710
Drug: Glucametacin (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucametacin (420 mg daily)
Trial: 31564841
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained daily living and routines)
Trial: 7588829
Drug: Gentamicin 4
RxNorm normalized name: gentamicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4 mg/kg q 24h i.v.
Trial: 7588829
Drug: Gentamicin 1.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 1.33 mg/kg q 8h i.v. (thrice-daily)
Trial: 7588829
Drug: Netilmicin 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 5.5 mg/kg q 24h i.v.
Trial: 2378175
Drug: Intravenous pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulse methylprednisolone 1000 mg
Trial: 2378175
Drug: Intravenous pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulse methylprednisolone 250 mg
Trial: 2378175
Drug: Both dosages
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosages of intravenous methylprednisolone
Trial: 31801940
Drug: Ofatumumab (300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years)
Trial: 23497636
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg idursulfase beta infusions
Trial: 23497636
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg idursulfase beta infusions
Trial: 23497636
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator infusions
Trial: 9210530
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone supplementation (rhGH, 0.15 mg/kg/d)
Trial: 9210530
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with adjuvant rhGH
Trial: 3519885
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) and hydrocortisone (HC) after TAM therapy
Trial: 29127492
Drug: 0.2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/kg dexmedetomidine (Dex-0.2 group)
Trial: 29127492
Drug: 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg dexmedetomidine (Dex-0.5 group)
Trial: 25706950
Drug: Usual family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual family based treatment (FBT)
Trial: 23237107
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks
Trial: 15556325
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 30 mg before surgery
Trial: 15556325
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection before surgery
Trial: 15556325
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 30 mg after surgery
Trial: 8908233
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection after surgery
Trial: 9322804
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methimazole (MMI) + 1.5 micrograms 1 alpha (OH)D3 (group B)
Trial: 9322804
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methimazole (MMI) (group A)
Trial: 30229852
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (rhPro-UK after Solitaire scaffold)
Trial: 24924486
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg/day for six months
Trial: 15885696
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mebendazole (MBZ)
Trial: 8213600
Drug: Intranasal propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal propranolol spray (5 mg/puff)
Trial: 3325934
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ciprofloxacin orally
Trial: 3619432
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ciprofloxacin intravenously
Trial: 3619432
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin orally
Trial: 30558006
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (HR) group, infused at a rate of 0.25 μg/kg/min, adjusted by 0.05 μg/kg/min as needed.
Trial: 30558006
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (LR) group, infused at a rate of 0.05 μg/kg/min.
Trial: 30558006
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (HR) group.
Trial: 30558006
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (LR) group.
Trial: 25042870
Drug: 1mg oral
RxNorm normalized name: AXITINIB 1MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg oral dose of risperidone
Trial: 22180560
Drug: Lamivudine dosing
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine dosing according to WHO weight band
Trial: 22180560
Drug: Lamivudine dosing
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine dosing according to FDA label
Trial: 20600017
Drug: pegylated interferon‐alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated interferon‐alfa‐2a (Peg‐IFNalfa‐2a) 180 µg/wk
Trial: 20600017
Drug: albinterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albinterferon alfa‐2b (albIFN) 900 µg every 2 weeks
Trial: 20600017
Drug: albinterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albinterferon alfa‐2b (albIFN) 1200 µg every 2 weeks
Trial: 18235117
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta 30,000 U subcutaneously once weekly for 24 weeks
Trial: 31513163
Drug: Enhanced external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced external counterpulsation therapy during standard drug therapy (study group)
Trial: 31513163
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug therapy (control group)
Trial: 28292320
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg three times a day
Trial: 26721135
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling combined with element calcium (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Trial: 26721135
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Trial: 11981075
Drug: i.v. calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. calcium folinate (50 mg/week)
Trial: 11981075
Drug: oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral calcium folinate (50 mg/week)
Trial: 11981075
Drug: oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral folic acid (45 mg/week)
Trial: 9615260
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg daily for 12 months (group A)
Trial: 383103
Drug: EMD 21657
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 21657 (3X300 mg)
Trial: 31487383
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus prednisone (0.5 or 1.0 mg/kg/day, tapered over 3 or 6 months)
Trial: 31487383
Drug: Prednisone alone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone alone (1.0 or 1.5 mg/kg/day, tapered over 12 or 18 months)
Trial: 26016150
Drug: Palliative external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative external beam radiotherapy with hypofractionation regimes (3 fractions of 6.5 Gy for a total dose of 19.5 Gy, 4 fractions of 6.5 Gy for a total dose of 26 Gy) and standard treatment schedule (total dose of 26 Gy)
Trial: 11127100
Drug: 0.75% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% metronidazole vaginal gel (5 g twice daily for five days)
Trial: 11127100
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (500 mg twice daily for seven days)
Trial: 9324103
Drug: Alpha1‐adrenoreceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1‐adrenoreceptor blocker (bunazosin)
Trial: 9324103
Drug: Beta1‐adrenoreceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta1‐adrenoreceptor blocker (metoprolol)
Trial: 27048670
Drug: Vitamin C/E
RxNorm normalized name: vitamin C/elderberry fruit/Echinacea purpurea 90 mg-100 mg-50 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C/E complex supplementation (100 IU of vitamin E + 500 mg of vitamin C) twice per day during radiotherapy
Trial: 24096631
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (2 weeks)
Trial: 24096631
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (8 weeks)
Trial: 20679159
Drug: Best-tasting solution
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best-tasting solution
Trial: 17357307
Drug: Peritoneal dialysis
RxNorm normalized name: Peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal dialysis solutions with low content of glucose degradation products
Trial: 17357307
Drug: Amino acid‐based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid‐based, icodextrin‐based or glycerol‐based dialysis solution
Trial: 17357307
Drug: Intraperitoneal drugs
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal drugs
Trial: 12661776
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/day) for 2 years
Trial: 10588313
Drug: Grepafloxacin 400
RxNorm normalized name: grepafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 400 mg od for 10 days
Trial: 10719007
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg bd for 10 days
Trial: 3776447
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg/kg followed by suxamethonium 1.5 mg/kg i.v.
Trial: 3776447
Drug: Enflurane with
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enflurane with suxamethonium 2 mg/kg
Trial: 30929823
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg/day until disease progression or unacceptable toxicity
Trial: 30929823
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg/day
Trial: 27841945
Drug: Greater expression
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater expression of intestinal cholesterol metabolism genes (NPC1L1, ABC‐G5, ABC‐G8, ABC‐A1, MTTP, SREBP‐2)
Trial: 26002728
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg resveratrol for 6 weeks
Trial: 21274547
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of a venotonic drug (micronized purified flavonoid fraction, Daflon 1,000 mg × 3) for 20 days
Trial: 21274547
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatment alone
Trial: 19846544
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention plus n-3 fatty acid supplementation (6 g/d)
Trial: 16895071
Drug: Risedronate, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate, 2.5 mg/day, daily
Trial: 16895071
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily
Trial: 9602595
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (saline) 50 ml
Trial: 9602595
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine solution with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Trial: 9602595
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 2% lidocaine with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Trial: 8022633
Drug: NASCIS dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASCIS dose of methylprednisolone
Trial: 3046231
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg, 4 times a day)
Trial: 3046231
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg, 4 times a day)